Cipla Ltd News

Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra_63416

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Rejuvenating Cipla: After global expansion, acquisitions on cards_63414

Having consolidated its presence across geographies, the pharma major is looking at acquisitions

Cipla looks to invest more in mRNA tech; holds discussions with firms_61928

Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the commercial growth engines

Cipla will use Covid-19 bulk drugs inventory when demand rises_61931

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said

Stocks to Watch: SBI, Cipla, Voda Idea, Gujarat Gas, Zensar, MGL, Welspun_61622

Stocks to Watch Today: The primary market too is likely to be abuzz with activity with three IPOs namely - Delhivery, Prudent Corporate Advisory Services IPO and Venus Pipes IPO open for subscription.

Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact_61494

For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts_48612

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug_45317

Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.

Cipla hits fresh all-time high in a volatile market; rallies 12% in 1 week_43487

Going forward, significant momentum in Cipla will likely continue due to US gains on the back of peptide portfolio unlocking and possible approvals and launches of gRevlimid, gAdvair and gAbraxane

Cipla gains 3%, hits record high; trades higher for 5th straight day_42329

Analysts at ICICI Securities have maintained a 'buy' rating on the stock with target price of Rs 1,100 on the stock

Cipla slips 5% as 2.5% equity changes hands on the BSE_32742

According to the disclosure made by the company, Y K Hamied, Chairman, and MK Hamied, Vice Chairman, sold 2,01,69,756 shares, representing 2.5 per cent of the total capital

Drugmaker Cipla to buy 32.49% stake in AMP Energy Green Eleven_27772

AMP Energy Green Eleven was incorporated on November 21, 2020, and is engaged in the business of generating and supplying electrical power generated using solar energy

Multiple triggers across key markets may support Cipla's recent rally_23575

In addition to the Q3 show, new launches offer upsides from current levels

Naina Lal Kidwai resigns from Cipla board_23538

The veteran banker noted that she has put in her papers to fulfil several other responsibilities and professional commitments

Pharma shares trade firm; Laurus up 2%, Sun Pharma nears 52-week high_12610

Sun Pharma, Cipla, Natco, Dr Reddy's, Torrent Pharma, Aurobindo Pharma and Strides have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from DCGI

Cipla receives EUA for oral antiviral drug to treat mild-to-moderate Covid_12271

Cipla will soon make Cipmolnu 200 mg capsules, which will be available at all leading pharmacies and Covid treatment centres across the country

Cipla stock rises on strong launch pipeline, FDA approval for injection_9310

Margin gains and steady growth in the Indian market to support the stock, say analysts.

Cipla gains 3% on USFDA's final approval for Lanreotide injection_9037

ICICI Securities remains positive on Cipla's calibrated approach of focusing more on branded products and core therapies across the world

Stocks to Watch: Airtel, ICICI, Hindalco, Shriram Properties, ONGC, Cipla_8992

Consumer Durable stocks are also likely to be in focus on Monday after the company have hiked prices for the third time this year

Glenmark, Alembic, Cipla: Pharma stocks on a booster dose this December_1947

Select pharma stocks look good on the technical charts and may jump up to 15 per cent in December. On the fundamental side, fears of Omicron variant spreading may also keep them in news and buzzing